Ka la 24 Phato, 2022, US Food and Drug Administration (FDA) e amohetse ibrutinib bakeng sa kalafo ea bakuli ba bana ba lilemo tse fetang 1 ba nang le lefu le sa foleng la graft-versus-host ( cGVHD ) ba fumanang Kamora ho hloleha ha 1- kapa mela e mengata. phekolo ea tsamaiso .Pontšo e amohetsoeng haholo-holo bakeng sa bakuli ba bana, ka kakaretso ea karabelo ea 60% bekeng ea 25, 'me litlhare tsa lithethefatsi li kenyelletsa li-capsules, matlapa le ho emisoa ka molomo.
Ibrutinib, BTK inhibitor co-developed by Pharmacics/Johnson & Johnson, ke kinase inhibitor e neng e amohetswe pele bakeng sa kalafo ya chronic lymphocytic leukemia hammoho le cell lymphoma le mafu a mang.
Suntech e tsepamisitse maikutlo ho nts'etsopele le tlhahiso ea li-intermediate tsa meriana le li-API tse sebelisang theknoloji e tala.Hajoale, k'hamphani ea rona e hlahisitse lihlahisoa tse tharo tse mahareng tsa ibrutinib ho kenyelletsa C AS: 143900-44-1 , C AS: 330792-70-6 , C AS: 330786-24-8 , kaofela ha tsona li rekisitsoe tlhahiso ea lifeme tsa GMP. .Har'a bona, bohareng ba C AS: 143900-44-1 bo hlahisoa ke theknoloji ea lik'hemik'hale-enzymatic , e nang le melemo ea ho sireletsa tikoloho e tala, theko e tlaase le boleng bo phahameng.Rea u amohela ho buisana le ho sebelisana!
Nako ea poso: Nov-04-2022